MAPT and Alzheimer disease: A total body dose of 0.5 Gy administered to neonatal NMRI mice has been shown to result in long-term cognitive dysfunction and enhanced level of total tau protein (Mapt), a marker of AD pathology, in the adult mouse brain [7].